Rapid Resolution of Psoriasis Following Low-Dose Interleukin-2 Monotherapy: A Case Report

Psoriasis is a chronic, immune-mediated inflammatory disease. Despite significant advancements in therapies, a considerable subset of patients either fails to achieve adequate response or experiences adverse effects. Herein, we present the case of a patient with a 20-year history of psoriasis, refractory to topical therapy. She received low-dose interleukin-2 (IL-2) monotherapy (500,000 IU subcutaneously daily for 80 consecutive days). A prompt and marked clinical improvement was noted. No adverse events were reported, and the patient remained free of new lesions after treatment discontinuation. To our knowledge, this is the first case of psoriasis successfully treated with low-dose IL-2 monotherapy, suggesting that this approach may represent a rapid and effective alternative for patients with psoriasis. Further evaluation in larger clinical studies is warranted.